PROSTATE CANCER ADVISOR

Prostate Cancer

Features

Prostate Cancer ADT Has Fewer Cardiovascular Risks Than Expected

Investigators found that men receiving androgen deprivation therapy for prostate cancer had a 1% rate of major adverse cardiovascular events.
Video May Aid in Precision Medicine for Prostate Cancer

In a study of men with prostate cancer or a family history of the disease, a higher proportion of men opted to view an educational video over personal genetic counseling prior to genetic testing.
PSA Density Plus MRI May Improve Detection of Clinically Significant Prostate Cancer

Combining PSA density with prostate MRI findings improves the predictive performance of PI-RADS in men without a prior prostate cancer diagnosis.
4Kscore May Help Predict Adverse Pathology at Radical Prostatectomy

In a study, a higher 4Kscore was significantly associated with a 16% greater risk of biochemical recurrence of prostate cancer following radical prostatectomy.
SABR Found to Improve Outcomes in Recurrent Oligometastatic HSPC

In patients with recurrent oligometastatic hormone-sensitive prostate cancer, stereotactic ablative radiation therapy decreased the risk of disease progression compared with observation alone, a phase 2 study found.
Genomic Alterations Linked to Outcomes in mCSPC

DNA sequencing in men with metastatic castration-sensitive prostate cancer revealed alterations in certain signaling pathways that predict worse overall survival and shorter progression time to castration-resistant disease.
Prostate Cancer Immunotherapy Alone Is Not Enough

So far, prostate cancer immunotherapy has shown only modest benefits. To greatly improve outcomes, immunotherapy will need to be combined with other treatments, according to the authors of a recent review.
Radiation Therapy After Prostate Surgery Worsens Sexual, Urinary Function

Allowing an approximately 24-month recovery period after prostate surgery before giving radiation therapy may be optimal for preserving erectile function provided oncologic control is not compromised, according to investigators.

Latest Prostate Cancer News

Metastatic Prostate Cancer: Investigators Ponder New Path to Improve Survival

September 30, 2022

Greater effort should be directed at detecting and aggressively treating prostate cancer metastasis earlier, an approach made possible with the advent of highly sensitive and specific molecular imaging techniques and potent anticancer agents.

Coffee Intake Linked to Longer Prostate Cancer-Specific Survival

September 30, 2022

Longer prostate cancer-specific survival seen for specific subgroups, including those with the CYP1A2 AA genotype

PSMA PET/CT Lymph Node Staging Can Predict Prostate Cancer Surgery Outcomes

Jody A. Charnow

September 29, 2022

Pelvic lymph node metastases visualized on PSMA PET/CT prior to prostate cancer surgery independently predicts an increased risk for biochemical disease progression, a study found.

Severity of Sleep Apnea and Related Hypoxia Tied to Cancer

September 27, 2022

Sleep apnea and related hypoxia more severe in obstructive sleep apnea patients with cancer compared with those without cancer

Study: 177Lutetium-PSMA-617 After 223Radium for mCRPC Safe, Effective

Jody A. Charnow

September 20, 2022

Treatment with 177lutetium-PSMA-617 (177Lu-PSMA) is safe and effective in patients with metastatic castration-resistant prostate cancer (mCRPC) who have previously received 223radium (223Ra), according to study findings presented at the European Society for Medical Oncology’s 2022 Congress (ESMO 2022) in Paris, France. In a study of 133 patients who participated in the RALU trial, Kambiz Rahbar,…

Radiologist preparing patient for PET-CT scanner.

Upstaging After PSMA PET for High-Risk Prostate Cancer Increasing

Natasha Persaud

September 19, 2022

Study findings suggest that PSMA PET results may alter treatment decisions in high-risk prostate cancer.

Novel Hormonal Therapies for nmCRPC Underused, Data Show

Jody A. Charnow

September 16, 2022

Investigators characterized practice patterns in the first-line treatment of nonmetastatic castration-resistant prostate cancer using real-world data.